Biotest AG (BTTAY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Biotest AG (BTTAY) trades at $24.21 with AI Score 48/100 (Grade C). Biotest AG is a global pharmaceutical company based in Dreieich, Germany, specializing in biological medicines for hematology, clinical immunology, and intensive care. Market cap: $1.88B, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for BTTAY: BTTAY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BTTAY against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BTTAY: the 1 perspectives are evenly split.
How is this calculated? →Biotest AG (BTTAY) Healthcare & Pipeline Overview
Biotest AG is a leading biotechnology firm focused on developing and commercializing biological medicines, with a strong emphasis on hematology, immunology, and critical care, driven by innovation and a commitment to addressing unmet medical needs.
What Is the Investment Thesis for BTTAY?
Biotest AG presents a unique value proposition in the biotechnology sector, driven by its diverse product portfolio and strategic focus on unmet medical needs. The company has a market capitalization of approximately $0.94 billion and a gross margin of 20.4%, indicating a solid operational foundation. Key growth catalysts include the increasing demand for biological medicines in hematology and immunology, projected to grow significantly in the coming years. Additionally, Biotest's integration into Grifols, S.A. provides enhanced resources for research and development, potentially accelerating product innovation and market penetration. However, the company faces risks such as regulatory challenges and competition from biosimilars, which could impact its market position. Investors should closely monitor these dynamics as they assess Biotest's growth potential.
Based on FMP financials and quantitative analysis
BTTAY Key Highlights
- Market capitalization of $1.88B, reflecting Biotest AG's position in the biotechnology sector.
- Gross margin of 20.4%, indicating efficient production and operational practices.
- Profit margin of -7.6%, highlighting the need for improved cost management strategies.
- Dividend yield of 0.12%, providing a modest return for investors.
- Employee base of 2,495, showcasing the company's scale and operational capacity.
Who Are BTTAY's Competitors?
BTTAY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GRFS Grifols, S.A. is a global healthcare company focused on plasma-derived medicines and other innovative solutions. The company | $7.21 | +0.77% | $6.10B | 45 |
| BAX Baxter International Inc. | $22.45 | -0.88% | $11.59B | 52 |
| CSL Carlisle Companies Incorporated | $365.27 | -0.40% | $14.78B | 87 |
| AMGN Amgen Inc. | $365.01 | -2.44% | $197.00B | 83 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BTTAY's Key Strengths?
- Established reputation in the biotechnology sector with over 75 years of experience.
- Diverse product portfolio addressing critical medical needs across multiple therapeutic areas.
- Strong research and development capabilities supported by Grifols, S.A.
- Global operational presence enhances market access and customer reach.
What Are BTTAY's Weaknesses?
- Negative profit margin of -7.6%, indicating potential operational inefficiencies.
- Dependence on a limited number of key products for revenue generation.
- Challenges in scaling production to meet increasing global demand.
- Exposure to regulatory risks in different markets.
What Could Drive BTTAY Stock Higher?
- Expansion of product offerings in the hematology sector to capture market growth.
- Continuous investment in research and development to drive innovation and product pipeline enhancement.
- Integration with Grifols, S.A. providing access to additional resources and market opportunities.
- Potential regulatory approvals for new therapies targeting unmet medical needs.
- Strategic partnerships with healthcare organizations to enhance distribution and market reach.
What Are the Key Risks for BTTAY?
- Financial-distress signal — its Altman Z-Score of 1.79 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-4.8%) — the business is not currently generating profit on shareholder capital.
- Regulatory changes that may impact product approvals and market access.
- Intense competition from established pharmaceutical and biotechnology companies.
- Emergence of biosimilars posing challenges to existing product lines.
- Economic fluctuations affecting healthcare spending and reimbursement rates.
What Are the Growth Opportunities for BTTAY?
- Growth opportunity 1: Biotest AG is poised to expand its product offerings in the hematology sector, targeting a market projected to reach $50 billion by 2028. The increasing prevalence of blood disorders and advancements in treatment options create a favorable environment for growth. Biotest's established reputation and innovative therapies position it to capture significant market share in this expanding field.
- Growth opportunity 2: The global immunology market is expected to grow at a CAGR of 9.5% through 2027, driven by rising autoimmune diseases and advancements in biological therapies. Biotest's portfolio, including Intratect and IgG Next Generation, targets key areas within this market, providing a strong foundation for growth as healthcare providers seek effective solutions for immune system disorders.
- Growth opportunity 3: Biotest's focus on developing therapies for infectious diseases, particularly in light of the COVID-19 pandemic, presents a significant growth avenue. The global market for infectious disease treatments is projected to reach $100 billion by 2025, driven by increased healthcare spending and the need for innovative therapies. Biotest's existing products, such as Trimodulin, position it well to capitalize on this trend.
- Growth opportunity 4: The company's integration with Grifols, S.A. enhances its research and development capabilities, allowing for accelerated product innovation. This partnership may lead to the development of new therapies and expansion into new geographic markets, particularly in regions with unmet medical needs, further driving growth.
- Growth opportunity 5: Biotest AG's commitment to sustainability and ethical practices aligns with increasing consumer demand for socially responsible companies. By focusing on sustainable production methods and transparent supply chains, Biotest can enhance its brand reputation and attract a broader customer base, particularly among healthcare providers prioritizing ethical sourcing.
What Opportunities Does BTTAY Have?
- Growing demand for biological medicines in hematology and immunology sectors.
- Expansion potential into emerging markets with unmet healthcare needs.
- Increased investment in research and development for innovative therapies.
- Strategic partnerships with healthcare organizations for collaborative growth.
What Threats Does BTTAY Face?
- Intense competition from established pharmaceutical and biotechnology companies.
- Potential regulatory changes impacting product approvals and market access.
- Emergence of biosimilars posing challenges to existing product lines.
- Economic fluctuations affecting healthcare spending and reimbursement rates.
What Are BTTAY's Competitive Advantages?
- Strong brand reputation built over decades in the biotechnology sector.
- Diverse product portfolio addressing critical healthcare needs.
- Established relationships with healthcare providers and institutions.
- Integration with Grifols, S.A. provides enhanced resources and capabilities.
- Commitment to innovation and research differentiates Biotest from competitors.
What Does BTTAY Do?
Biotest AG, founded in 1946, operates from its headquarters in Dreieich, Germany, as a prominent player in the pharmaceutical industry. Initially established as Biotest Serum-Institut GmbH, the company transitioned to Biotest Aktiengesellschaft in 1986, reflecting its growth and evolution in the biotechnology sector. Biotest specializes in the research, development, manufacturing, and commercialization of biological medicines, strategically organized into Therapy, Plasma & Services, and Other divisions. Its comprehensive product portfolio encompasses treatments for hematology, clinical immunology, and intensive care medicine. Notable products include Haemoctin and Vihuma for hemophilia A, and Haemonine for hemophilia B, addressing both acute episodes and long-term prevention. Additionally, Biotest's infectious disease portfolio features therapies such as Cytotect CP for cytomegalovirus and Varitect for varicella zoster virus. The company also provides several Hepatitis B-related products and treatments for immune system disorders, such as Intratect and IgG Next Generation. Biotest’s commitment to innovation is evident in its specialized treatments, including Trimodulin for community-acquired pneumonia and COVID-19, and Pentaglobin for bacterial infections. As of January 21, 2022, Biotest AG operates as a subsidiary of Grifols, S.A., enhancing its global reach and operational capabilities.
What Products and Services Does BTTAY Offer?
- Develops and manufactures biological medicines for various medical conditions.
- Offers treatments for hematology, clinical immunology, and intensive care medicine.
- Provides therapies for hemophilia, infectious diseases, and immune system disorders.
- Engages in research and development to innovate new treatment options.
- Operates globally, supplying products to healthcare providers and institutions.
- Functions as a subsidiary of Grifols, S.A., enhancing operational capabilities.
How Does BTTAY Make Money?
- Generates revenue through the sale of biological medicines to healthcare providers.
- Engages in partnerships and collaborations for research and development.
- Utilizes a tiered pricing strategy to cater to different market segments.
- Focuses on expanding product offerings to address unmet medical needs.
- Leverages its global presence to access diverse markets and customer bases.
What Industry Does BTTAY Operate In?
The biotechnology industry is experiencing robust growth, driven by advancements in biological therapies and increasing demand for innovative treatments. The global market for biological medicines is projected to expand significantly, fueled by rising incidences of chronic diseases and an aging population. Biotest AG competes in a dynamic landscape, facing competition from established pharmaceutical companies and emerging biotech firms. The company's focus on specialized therapies positions it well to capitalize on market trends, particularly in hematology and immunology, where there is a growing need for effective treatment options.
Who Are BTTAY's Key Customers?
- Healthcare providers, including hospitals and clinics.
- Pharmaceutical distributors and wholesalers.
- Patients requiring specialized treatments for chronic conditions.
- Research institutions and laboratories involved in clinical studies.
- Government health agencies and organizations.
F-Score 4/9Financial Health
Biotest AG's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.79 places it in the distress zone, a signal of elevated financial risk.
ROE -5%Key Financial Metrics
Return on equity for Biotest AG stands at -4.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -1.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.93 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.0%, the inverse of the P/E and a quick read on earnings relative to price.
Biotest AG (BTTAY) Valuation Context
Valued at $1.88B, BTTAY is classified as a small-cap stock. Relative to its peer group, BTTAY's quantitative score of 48/100 is below the peer average of 69/100.
BTTAY Revenue & Earnings Trend
In Q1 2025, BTTAY generated $124.2M in top-line revenue, marking a sequential decrease of 39.0%. The company recorded a net loss of $21.4M, with diluted EPS of $-0.28. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, BTTAY averaged $-0.08 in diluted EPS.
Company Profile
Biotest AG operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Dreieich, DE. The company is led by CEO Jorg Schuttrumpf. BTTAY has traded publicly since 2022.
BTTAY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- BTTAY's insider activity suggests confidence; recent buys could signal positive internal expectations.
- Community sentiment seems cautiously optimistic, with discussions focusing on potential growth catalysts.
- Market perception acknowledges Biotest's specialized plasma products, which could offer resilience.
- Biotest's strategic focus on niche markets may provide a competitive edge against larger players.
Bear Case
- Community chatter reveals concerns about Biotest's limited scale compared to industry giants.
- Recent market developments highlight increased competition in the plasma-derived therapies sector.
- Insider selling, if present, could indicate concerns about short-term performance (data unavailable).
- Overall market perception reflects some uncertainty about Biotest's long-term growth trajectory in a dynamic healthcare landscape.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2025 | $124M | -$21M | -$0.28 |
| Q4 2024 | $204M | -$4M | -$0.05 |
| Q3 2024 | $151M | -$9M | -$0.12 |
| Q2 2024 | $157M | $10M | $0.13 |
Based on FMP financials and quantitative analysis
BTTAY Latest News
No recent news available for BTTAY.
BTTAY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BTTAY.
Price Targets
Wall Street price target analysis for BTTAY.
BTTAY MoonshotScore
What does this score mean?
The MoonshotScore rates BTTAY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jorg Schuttrumpf
CEO
Jorg Schuttrumpf has extensive experience in the pharmaceutical and biotechnology sectors, having held various leadership positions throughout his career. He has a strong academic background in life sciences and business management, equipping him with the skills necessary to lead Biotest AG effectively. Schuttrumpf has been instrumental in driving the company's strategic initiatives and operational improvements, ensuring alignment with market demands.
Track Record: Under Schuttrumpf's leadership, Biotest AG has successfully expanded its product portfolio and enhanced its research capabilities. He has overseen the integration of Biotest into Grifols, S.A., positioning the company for future growth and innovation.
Biotest AG ADR Information Unsponsored
An American Depositary Receipt (ADR) represents shares of a foreign company traded on U.S. exchanges. Biotest AG's ADR allows U.S. investors to gain exposure to the company's stock while trading in U.S. dollars, simplifying the investment process.
- Home Market Ticker: BTTA on the Frankfurt Stock Exchange, Germany
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: BTTA
BTTAY OTC Market Information
The OTC Other tier includes stocks that do not meet the listing requirements for major exchanges like NYSE or NASDAQ. These stocks may have less stringent reporting standards, resulting in varying levels of transparency and liquidity compared to listed companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity can result in higher volatility and difficulty in executing trades.
- Less stringent reporting requirements may lead to less transparency in financial performance.
- Potential for price manipulation due to lower trading volumes.
- Increased exposure to regulatory scrutiny compared to listed companies.
- Review financial statements and disclosures available for Biotest AG.
- Analyze the competitive landscape and market positioning.
- Assess the company's growth strategy and product pipeline.
- Monitor regulatory developments affecting the biotechnology sector.
- Evaluate the impact of currency fluctuations on investment returns.
- Established history since 1946, indicating stability and experience.
- Partnership with Grifols, S.A., a reputable global healthcare company.
- Diverse product portfolio addressing critical healthcare needs.
- Active engagement in research and development for innovative therapies.
Common Questions About BTTAY (Healthcare)
What does Biotest AG do?
Biotest AG develops, manufactures, and sells biological medicines, focusing on critical areas such as hematology, clinical immunology, and intensive care medicine. The company offers a range of therapies for conditions like hemophilia, infectious diseases, and immune system disorders, with a commitment to addressing unmet medical needs through innovation.
What do analysts say about BTTAY stock?
Analysts generally view Biotest AG as a company with significant growth potential, particularly in the biotechnology sector. Key valuation metrics, such as its gross margin of 20.4%, suggest operational efficiency, while the company's strategic focus on expanding its product portfolio aligns with market trends. Investors may want to evaluate these factors when evaluating the stock's future performance.
What are the main risks for BTTAY?
Biotest AG faces several risks, including regulatory challenges that may affect product approvals and market access. Additionally, intense competition from established pharmaceutical companies could impact market share. The emergence of biosimilars poses a threat to existing product lines, while economic fluctuations may influence healthcare spending and reimbursement rates, affecting overall revenue.
What are the key factors to evaluate for BTTAY?
Biotest AG (BTTAY) holds an AI score of 48/100 (low). Not financial advice.
How frequently does BTTAY data refresh on this page?
BTTAY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BTTAY's recent stock price performance?
Biotest AG (BTTAY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established reputation in the biotechnology sector with over 75 years of experience. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BTTAY overvalued or undervalued right now?
Valuing Biotest AG (BTTAY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BTTAY?
Before investing in Biotest AG (BTTAY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.